Ability of recombinant factor VIIa to generate thrombin during inhibition of tissue factor in human subjects

Circulation

Volumn 103, Issue 21, 2001, Pages 2555-2559

  Friederich, Philip W ^a   Levi, Marcel ^a   Bauer, Kenneth A ^b   Vlasuk, George P ^c   Rote, William E ^c   Breederveld, Daan ^a   Keller, Tijmen ^a   Spataro, Marco ^a   Barzegar, Samad ^b   Büller, Harry R ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b HARVARD MEDICAL SCHOOL   (United States)

^c Dendreon   (United States)

Author keywords

Anticoagulants; Coagulation; Drugs; Inhibitors; Thrombosis

Indexed keywords

ANTICOAGULANT PROTEIN; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 9; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT NEMATODE ANTICOAGULANT PROTEIN C2; THROMBIN; THROMBIN ANTITHROMBIN COMPLEX; THROMBOPLASTIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLEEDING; BLOOD CLOTTING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; HUMAN; IN VIVO STUDY; MALE; NEMATODE; NORMAL HUMAN; PRIORITY JOURNAL; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL; THROMBOSIS;

EID: 0035967490     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.103.21.2555     Document Type: Article

References (29)

1. The tissue factor pathway: How it has become a "prima ballerina"
2. Biochemistry and physiology of blood coagulation
3. Disseminated intravascular coagulation
4. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques
5. Pathophysiology and clinical significance of atherosclerotic plaque rupture
6. Local inhibition of tissue factor reduces the thrombogenicity of disrupted human atherosclerotic plaques
7. Clinical evaluation of rNAPc2, an inhibitor of the fVIIa/tissue factor coagulation complex
8. Early clinical evaluation of rNAPc2, a novel inhibitor of blood coagulation factor VIIa/tissue factor
9. Anticoagulant repertoire of the hookworm Ancylostoma caninum
10. A possible mechanism of action of activated factor VII independent of tissue factor
11. Treatment of patients with factor VIII and factor IX inhibitors with special focus on the use of recombinant factor VIIa
12. Treatment of a patient with Bernard-Soulier syndrome and recurrent nosebleeds with recombinant factor VIIa
13. A patient with Glanzman thrombasthenia and epistaxis successfully treated with recombinant factor VIIa
14. The effect of recombinant factor VIIa in healthy volunteers receiving acenocoumarol to an INR above 2.0
15. Detection of factor X activation in humans
16. Factor IX is activated in vivo by the tissue factor mechanism
17. Direct detection of activated protein C in blood from human subjects
18. A novel enzyme capture assay for determining recombinant fVIIa activity in human plasma
19. Activation of factor IX by the reaction product of tissue factor and factor VII: Additional pathway for initiating blood coagulation
20. The activation of factor X and prothrombin by recombinant factor VIIa in vivo is mediated by tissue factor
21. Use of human factor VIIa in the treatment of two hemophilia A patients with high-titer inhibitors
22. Activated factor VII activates factors IX and X on the surface of activated platelets
23. The mechanism of factor VIIa "by-passing" hemophilia: Empirical and theoretical studies
24. Blood-borne tissue factor: Another view of thrombosis
25. Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees
26. Inhibitory mechanism of the protein C pathway on tissue factor-induced thrombin generation
27. Tissue factor pathway inhibitor (TFPI) dose-dependently inhibits coagulation activation without influencing the fibrinolytic and cytokine response during human endotoxemia
28. Acute myocardial infarction following administration of recombinant activated factor VII in a patient with haemophilia A and inhibitor
29. The treatment of bleeding in acquired haemophilia with recombinant factor VIIa: A multicentre study